ImageneBio (IMA) risk factors, FY2024 10-K

Risks Related to Our Strategic Alternatives Review Process

1. 01We undertook a comprehensive review of strategic alternatives, including identifying and reviewing potential candidates for a merger
2. 02we could potentially lose key personnel during the pendency of the Merger; and
3. 03The occurrence of any of these events individually or in combination could materially and adversely affect our results of operations, business, and our common stock price
4. 04We are substantially dependent on our remaining employees to facilitate the consummation of the Merger
5. 05Even if we are successful in completing a strategic transaction, we may be exposed to other operational and financial risks
6. 06If we do not complete the Merger, we may face substantial competition for attractive counterparties for any proposed strategic transactions
7. 07We have never paid and, other than in connection with the Merger, do not intend to pay any cash dividends in the foreseeable future, so any returns will be limited to the value of our capital stock
8. 08We may become involved in litigation, including securities class action litigation, which could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages

Risks Related to Our Limited Operating History, Financial Position, and Capital Requirements

1. 09We are a targeted oncology company with a limited operating history
2. 10We have incurred significant net losses since our inception and, if we continue to progress the development of our product candidates, anticipate that we will continue to incur losses for the foreseeable future
3. 11future accounting pronouncements or changes in our accounting policies
4. 12We have no products approved for commercial sale and have not generated any revenue from product sales
5. 13maintain a continued acceptable safety profile of our products following approval
6. 14the costs of establishing or contracting for sales and marketing capabilities if we obtain regulatory approvals to market our product candidates
7. 15Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates
8. 16We have recently undertaken internal restructuring activities, and may do so again in the future. The assumptions underlying these activities may prove to be inaccurate, or we may fail to achieve the expected benefits therefrom

Risks Related to the Development of our Targeted Oncology and Other Programs and Product Candidates

1. 17If we continue to progress the development of our product candidates, we may not be able to successfully complete clinical trials for our ongoing targeted oncology program or our current product candidate
2. 18Our lead program is focused on the development of oncology therapeutics for patients with genetically defined or biomarker-driven cancers, which is a rapidly evolving area of science, and the approach we have taken to discover and develop drugs is novel and may never lead to approved or marketable products
3. 19Clinical product development involves a lengthy and expensive process, with an uncertain outcome
4. 20Interim, top-line, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to confirmation, audit and verification procedures that could result in material changes in the final data
5. 21If we continue to progress the development of our product candidates, we may incur additional costs or experience delays in initiating or completing, or ultimately be unable to complete, development and commercialization
6. 22regulators may revise the requirements for approving our product candidates, or such requirements may not be as we currently anticipate
7. 23If we continue to progress the development of our product candidates and experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented
8. 24In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as do our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors’ product candidates
9. 25factors we may not be able to control that may limit patients, principal investigators or staff or clinical site availability
10. 26If we continue to progress the development of our product candidates, we may not be able to file INDs, or similar applications for our programs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA or other regulatory authorities may not permit us to proceed
11. 27Our clinical trials or those of our current or future collaborators may reveal significant adverse events not seen in our preclinical or nonclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates
12. 28We currently conduct clinical trials for our product candidates outside the United States, and the FDA, the EMA, the MHRA and comparable foreign regulatory authorities may not accept data from such trials
13. 29If we continue to progress the development of our product candidates, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional product candidates, our business could be materially harmed
14. 30it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates, thereby limiting our ability to develop, diversify and expand our product portfolio
15. 31the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change such that our clinical data are insufficient for approval
16. 32Pandemics, epidemics, or any outbreak of an infectious disease, may materially and adversely affect our business and our financial results and could cause a disruption to the continued development of our product candidates
17. 33If we continue to progress the development of our product candidates, we may need to reformulate our product candidates which could require additional nonclinical studies or clinical trials and delay the development or regulatory approval of such product candidates

Risks Related to Commercialization

1. 34We face substantial competition, which may result in others discovering, developing, or commercializing products before or more successfully than we do if we continue to progress development
2. 35organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization
3. 36If the market opportunities for our programs and product candidates are smaller than we estimate or if any regulatory approval that we obtain is based on a narrower definition of the patient population, our revenue and ability to achieve profitability will be adversely affected, possibly materially
4. 37If we continue to progress the development of our product candidates and our product candidates do not achieve broad market acceptance, the revenue that we generate from their sales may be limited, and we may never become profitable
5. 38events in targeted oncology, immune-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements, and potential regulatory delays in the testing or approvals of our product candidates
6. 39potential product liability claims
7. 40neither experimental nor investigational

Risks Related to Our Reliance on Third Parties

1. 41We do not have the ability to independently conduct clinical trials. We rely and expect to continue to rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct or otherwise support clinical trials for our product candidates
2. 42form relationships with other entities, some of which may be our competitors
3. 43We have entered into collaborations and may enter into additional collaborations in the future, and we might not realize the anticipated benefits of such collaborations
4. 44In addition, funding provided by a collaborator might not be sufficient to advance product candidates under the collaboration
5. 45Any one or more of these risks, if realized, could reduce or eliminate revenue from product candidates under our collaborations, and could have a material adverse effect on our business, financial condition, results of operations, and/or growth prospects
6. 46Our product candidates may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
7. 47The third parties upon whom we rely for the supply of the active pharmaceutical ingredients used in our product candidates are our sole source of supply, and if we continue to progress the development of our product candidates, the loss of any of these suppliers could significantly harm our business
8. 48We may seek to establish additional collaborations, and, if we are not able to establish them on commercially reasonable terms, or at all, we may have to alter our development and commercialization plans

Risks Related to Our Intellectual Property

1. 49If we are unable to adequately protect and enforce our trade secrets, our business and competitive position would be harmed
2. 50We may initiate, become a defendant in, or otherwise become party to lawsuits to protect or enforce our intellectual property rights, which could be expensive, time-consuming, and unsuccessful
3. 51Intellectual property litigation and administrative patent office patent validity challenges in one or more countries could cause us to spend substantial resources and distract our personnel from their normal responsibilities
4. 52We may not obtain or grant licenses or sublicenses to intellectual property rights in all markets on equally or sufficiently favorable terms with third parties
5. 53If we fail to comply with our obligations in any agreements under which we may license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
6. 54the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our future licensors and us and our partners
7. 55Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our current or future product candidates
8. 56We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might subject us to infringement claims or adversely affect our ability to develop and market our current or future product candidates
9. 57Intellectual property rights do not guarantee commercial success of current or future product candidates or other business activities. Numerous factors may limit any potential competitive advantage provided by our intellectual property rights

Risks Related to Government Regulation

1. 58Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
2. 59We may seek priority review designation for one or more of our other product candidates, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process
3. 60We may seek orphan drug designation for certain of our product candidates, and we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation, including the potential for market exclusivity
4. 61A breakthrough therapy designation and fast track designation by the FDA, even if granted, may not lead to a faster development, regulatory review or approval process, and each designation does not increase the likelihood that any of our product candidates will receive regulatory approval in the United States
5. 62Accelerated approval by the FDA, even if granted for our current or any other future product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive regulatory approval
6. 63The FDA, the EMA, the MHRA and other regulatory authorities may implement additional regulations or restrictions on the development and commercialization of our product candidates, and such changes can be difficult to predict
7. 64Healthcare legislative reform measures may have a material adverse effect on our business and results of operations
8. 65If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
9. 66injunctions or the imposition of civil or criminal penalties
10. 67European data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information
11. 68Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs

Risks Relating to Employee Matters and Managing Growth

1. 69Our future success depends on our ability to retain key executives and experienced scientists and to attract, retain and motivate qualified personnel
2. 70We and our third-party providers may be unable to adequately protect our information systems from cyberattacks, which could result in the disclosure of confidential or proprietary information, including personal data, damage our reputation, and subject us to significant financial and legal exposure
3. 71Artificial intelligence presents risks and challenges that can impact our business including by posing security risks to our confidential information, proprietary information, and personal data
4. 72We may be unable to successfully integrate acquisitions, which may adversely impact our operations
5. 73If we continue to progress the development of our product candidates, expand our development and regulatory capabilities and potentially implement sales, marketing and distribution capabilities, we may encounter difficulties in managing our growth, which could disrupt our operations

Risks Related to Our Common Stock

1. 74The dual class structure of our common stock may limit our stockholders’ ability to influence corporate matters and may limit visibility with respect to certain transactions
2. 75Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
3. 76Changes in tax legislation could adversely affect our business and financial condition
4. 77Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
5. 78the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock
6. 79Our bylaws designate specific courts as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us
7. 80Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations
8. 81Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading
9. 82exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved and some of the disclosure requirements of the Dodd-Frank Act relating to compensation of executive officers
10. 83We will continue to incur costs as a result of operating as a public company, and our management will be required to devote substantial time to compliance initiatives
11. 84Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
12. 85If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline